Chris Slavinsky
Former General Counsel and Head of Compliance
Bio:
Chris Slavinsky is the Managing Partner of CSM Advisors, where he provides strategic legal, compliance, and business development counsel to pharmaceutical, biotech, and medical device companies across the development and commercialization continuum. Mr. Slavinsky brings more than 25 years of experience leading life sciences transactions, with a track record of structuring and closing strategic deals, including transformational M&A, R&D collaborations, and asset divestitures at companies ranging from global pharmaceutical leaders to emerging biotechnology firms. In April 2026, Mr. Slavinsky supported the sale of Corstasis Therapeutics to Esperion Therapeutics.
Prior to founding CSM Advisors, Mr. Slavinsky served as Chief Business Development & Legal Officer at HanAll BioPharma, Chief Business & Legal Officer for Coherus Biosciences, General Counsel at Pharmacosmos Therapeutics, and General Counsel and Head of Business Development at Prometheus Biosciences. He worked at Takeda in a senior BD role and spent 17+ years at Pfizer in a range of legal leadership positions, with a focus on transactions. He received his J.D. from Washington University in St. Louis School of Law, an M.S. in Biochemistry and Molecular Biology from Thomas Jefferson University, and a B.S. in Biochemistry from the State University of New York at Stony Brook.